SARS-CoV-2 testing at the Seattle Vaccine and Prevention CRS (30331)

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2020
  • Known Financial Commitments (USD)

    $299,401
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    FRED HUTCHINSON CANCER RESEARCH CENTER
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Project Summary/AbstractOn March 11, 2020, the World Health Organization declared that the rapid spread of the novel coronavirus,SARS-CoV-2, and its associated disease, COVID-19, had become a global pandemic. The ongoing crisis calls for the involvement of clinical research sites (CRSs) to work rapidly and efficiently toward therapeutic andpreventative measures to control the epidemic. Our CRS, the Seattle Vaccine Trials Unit (VTU), has vast priorexperience conducting observational cohort studies and phase 1-2b clinical trials of preventative HIV vaccinesand other HIV prevention modalities. We propose bringing this infrastructure and experience to the field of SARS-CoV-2 clinical research. Our proposal is both to expand the scope of research activity at our CRS and to involvenew venues for protocol conduct. Onsite CRS activity will encompass natural history studies of recoveredCOVID-19 patients, as well as early to late phase vaccine protocols. New venues will be opened and developedin order to effectively conduct COVID-19 research with appropriate infection prevention procedures to preventSARS-CoV-2 transmission. Such new venues will include temporary structures that will provide capability toconduct clinical research in areas with continued SARS-CoV-2 transmission as specific areas with outbreaks arenoted during the course of the epidemic.